Computer-Based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton

Keyphrases

• Synergize 100%
• Salirasib 100%
• Cytoskeleton 100%
• Computer-based 100%
• LIMK1 100%
• Cell Motility 60%
• GTPase-activating Protein 60%
• Cofilin 60%
• Neurofibromin 60%
• EphA3 40%
• LIM Kinase 2 40%
• Phosphorylation 20%
• Kinase Activity 20%
• Drug Combination 20%
• Cell Proliferation 20%
• RAS Inhibitors 20%
• Molecular Modeling 20%
• Soft Agar 20%
• Actin 20%
• GTPase 20%
• Active Sites 20%
• Colony Formation 20%
• Tumor Cell Proliferation 20%
• ATP Binding Site 20%
• Novel Inhibitors 20%
• Neurofibromatosis 20%
• PAK1 20%
• Anchorage-independent 20%
• Tumor Cell Migration 20%
• Mitogen-activated Protein 20%
• Ephrin-A 20%
• Severance 20%
• Ras GTPase-activating Proteins 20%
• Substrate-binding Pocket 20%
• Actin Depolymerizing Factor 20%
• Rac GTPase 20%

Biochemistry, Genetics and Molecular Biology

• Actin 100%
• Cytoskeleton 100%
• LIMK1 100%
• GTPase-activating Protein 80%
• Kinase 60%
• Phosphotransferase 60%
• Cell Motility 60%
• Cofilin 60%
• GTPase 40%
• Cell Migration 20%
• Eicosanoid Receptor 20%
• Enzyme 20%
• Binding Site 20%
• Adenosine Triphosphate 20%
• Tumor Progression 20%
• Cell Proliferation 20%
• Colony Formation 20%
• Molecular Model 20%
• Molecular Modeling 20%
• Agar 20%
• Active Site 20%
• Actin Depolymerizing Factor 20%
• Cell Anchorage 20%
• P21-Activated Kinases 20%
• Ephrin 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Salirasib 100%
• Actin 100%
• Guanosine Triphosphatase Activating Protein 100%
• Neurofibromin 75%
• Cofilin 75%
• Guanosine Triphosphatase 50%
• LIM Kinase 50%
• Malignant Neoplasm 25%
• Phosphotransferase 25%
• Combination Drug 25%
• Tumor Growth 25%
• Neoplasm 25%
• Agar 25%
• Binding Site 25%
• Mitogenic Agent 25%
• Adenosine Triphosphate 25%
• Ephrin Receptor A3 25%
• P21 Activated Kinase 1 25%
• Ephrin 25%
• Neurofibromatosis 25%
• Actin Depolymerizing Factor 25%